Abbott Wins Unrestricted Use Of Stent Patent

Law360, New York (August 8, 2007, 12:00 AM EDT) -- A federal judge has adopted Abbott Laboratories’s interpretation of its settlement of a coronary stent patent dispute with Medinol Ltd., finding that Abbott may exploit the patent however it pleases rather than just to manufacture a specific product.

Judge Shira A. Scheindlin of the U.S. District Court for the Southern District of New York on Tuesday granted Abbott’s motion to enforce the settlement and denied Medinol’s. Abbott had argued that the settlement’s licensing arrangement was unrestricted regarding the patent’s use, while Medinol said the deal was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.